Advertisement
U.S. markets open in 49 minutes

Taysha Gene Therapies, Inc. (TSHA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.2900-0.2100 (-8.40%)
At close: 04:00PM EST
2.2895 -0.00 (-0.02%)
Pre-Market: 08:36AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close2.5000
Open2.4800
Bid2.2600 x 1800
Ask2.2900 x 900
Day's Range2.2100 - 2.5496
52 Week Range0.5000 - 3.8900
Volume1,895,848
Avg. Volume1,979,798
Market Cap428.138M
Beta (5Y Monthly)-0.13
PE Ratio (TTM)N/A
EPS (TTM)-2.8700
Earnings DateMar 26, 2024 - Apr 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TSHA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Taysha Gene Therapies, Inc.
    Daily – Vickers Top Buyers & Sellers for 08/17/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    6 months agoArgus Research
View more
  • GlobeNewswire

    Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

    DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today provided an update on its deprioritized pipeline programs as part of an ongoing effort to help support their further potential development. Taysha has been working to find ways to advance its deprio

  • Simply Wall St.

    Owning 39% shares,institutional owners seem interested in Taysha Gene Therapies, Inc. (NASDAQ:TSHA),

    Key Insights Significantly high institutional ownership implies Taysha Gene Therapies' stock price is sensitive to...

  • GlobeNewswire

    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    DALLAS, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that, on February 1, 2024, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 180,000 shares of the Company's common stock in connection with th